(Q34272283)

1 August 2017

Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis (English)

1 reference

1 August 2017

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis (English)

1 reference

https://api.crossref.org/works/10.1164/RCCM.200310-1380OC

25 March 2024

0 references

6

Richard E Chaisson

1 reference

1 August 2017

8

Jacques H Grosset

1 reference

1 August 2017

1

Eric L Nuermberger

1 reference

1 August 2017

Tetsuyuki Yoshimatsu

2

1 reference

1 August 2017

Sandeep Tyagi

3

1 reference

1 August 2017

Eric L. Nuermberger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578218

25 March 2024

Richard J. O'Brien

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578218

25 March 2024

Andrew N. Vernon

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578218

25 March 2024

William R. Bishai

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578218

25 March 2024

Jacques H. Grosset

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578218

25 March 2024

language of work or name

English

0 references

publication date

24 October 2003

1 reference

full work available at URL

1 August 2017

https://www.atsjournals.org/doi/pdf/10.1164/rccm.200310-1380OC

1 reference

https://api.crossref.org/works/10.1164/RCCM.200310-1380OC

American Journal of Respiratory and Critical Care Medicine

25 March 2024

published in

1 reference

1 August 2017

169

1 reference

1 August 2017

421-426

1 reference

1 August 2017

3

1 reference

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

1 August 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Whither short-course chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Tuberculosis. Scientific blueprint for tuberculosis drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Statistics in practice. Comparing the means of several groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

A selective oleic acid albumin agar medium for tubercle bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200310-1380OC

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

21 January 2018

8

1 reference

https://api.crossref.org/works/10.1164/RCCM.200310-1380OC

Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects

25 March 2024

11

1 reference

https://api.crossref.org/works/10.1164/RCCM.200310-1380OC

Short-course therapy of acute cystitis: a brief review of therapeutic strategies

25 March 2024

14

1 reference

https://api.crossref.org/works/10.1164/RCCM.200310-1380OC

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

25 March 2024

21

1 reference

https://api.crossref.org/works/10.1164/RCCM.200310-1380OC

Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results

25 March 2024

31

1 reference

https://api.crossref.org/works/10.1164/RCCM.200310-1380OC

25 March 2024

Identifiers

1 reference

1 August 2017

1 reference